Cinacalcet corrects hypercalcemia in mice with an inactivating Gα_{11} mutation

Sarah A. Howles, Fadil M. Hannan, Caroline M. Gorvin, Sian E. Piret, Anju Paudyal, Michelle Stewart, Tertius A. Hough, M. Andrew Nesbit, Sara Wells, Stephen D.M. Brown, Roger D. Cox, and Rajesh V. Thakker

1 Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. 2 Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom. 3 Mammalian Genetics Unit and Mary Lyon Centre, Medical Research Council (MRC) Harwell Institute, Harwell Science and Innovation Campus, United Kingdom. 4 Biomedical Sciences Research Institute, Ulster University, Coleraine, United Kingdom.

Introduction

Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant disorder of extracellular calcium (Ca^{2+}) homeostasis characterized by lifelong elevations in serum calcium concentrations in association with normal or mildly elevated serum parathyroid hormone (PTH) concentrations, and changes in urine flow, calcium excretion, and fractional calcium resorption. The CaSR, a widely expressed family C GPCR that regulates PTH secretion and urinary calcium excretion, is involved in regulating calcium homeostasis. The CaSR is a widely expressed family C GPCR that regulates PTH secretion and urinary calcium excretion, and is responsible for detecting changes in extracellular calcium concentration and transducing this information to the cell. The CaSR family includes the transient receptor potential (TRP) channels, which are calcium-permeable ion channels that are activated by changes in calcium concentration. The CaSR also regulates calcium homeostasis by transducing calcium concentration changes into multiple intracellular signaling cascades in the parathyroid glands and kidneys. In the parathyroid glands, the CaSR has been shown to couple to the Gα_{11} protein family, which activates phospholipase C (PLC), thereby increasing intracellular calcium (Ca^{2+}).

Loss-of-function mutations of GNA11, which encodes G-protein subunit α_{11} (Gα_{11}), a signaling partner for the calcium-sensing receptor (CaSR), result in familial hypocalciuric hypercalcemia type 2 (FHH2). FHH2 is characterized by hypercalcemia, inappropriately normal or raised parathyroid hormone (PTH) concentrations, and normal or low urinary calcium excretion. A mouse model for FHH2 that would facilitate investigations of the in vivo role of Gα_{11} and the evaluation of calcimimetic drugs, which are CaSR allosteric activators, is not available. We therefore screened DNA from > 10,000 mice treated with the chemical mutagen N-ethylnitrosourea (ENU) for GNA11 mutations and identified a Gα_{11} variant, Asp195Gly (D195G), which downregulated CaSR-mediated intracellular calcium signaling in vitro, consistent with it being a loss-of-function mutation. Treatment with the calcimimetic cinacalcet rectified these signaling responses. In vivo studies showed mutant heterozygous (GNA11^{+/-}GNA11^{+/+}) and homozygous (GNA11^{+/-}GNA11^{+/+}) mice to be hypercalcemic with normal or increased plasma PTH concentrations and normal urinary calcium excretion. Cinacalcet (30mg/kg orally) significantly reduced plasma albumin–adjusted calcium and PTH concentrations in GNA11^{+/-}GNA11^{+/+} and GNA11^{+/-}GNA11^{+/+} mice. Thus, our studies have established a mouse model with a germline loss-of-function Gα_{11} mutation that is representative for FHH2 in humans and demonstrated that cinacalcet can correct the associated abnormalities of plasma calcium and PTH.

Authorship note: SAH, FMH, and CMG contributed equally to this work.

Conflict of interest: FMH and RVT have received grant funding from NPS/Shire Pharmaceuticals and GlaxoSmithKline for studies involving the use of calcium-sensing receptor (CaSR) allosteric inhibitors. RVT has also received grants from Novartis Pharma AG and the Marshall Smith Syndrome Foundation for unrelated studies. SDMB declares ownership of shares in Pulmagen Therapeutics.

Loss-of-function mutations of GNA11, which encodes G-protein subunit α_{11} (Gα_{11}), a signaling partner for the calcium-sensing receptor (CaSR), result in familial hypocalciuric hypercalcemia type 2 (FHH2). FHH2 is characterized by hypercalcemia, inappropriately normal or raised parathyroid hormone (PTH) concentrations, and normal or low fractional excretion of calcium (1–4). FHH is caused by a reduction in the sensitivity of the CaSR signaling pathway to alterations in the prevailing Ca^{2+} concentration ([Ca^{2+}]), which in turn leads to decreased parathyroid PTH secretion and urinary calcium excretion. The CaSR is a widely expressed family C GPCR that regulates PTH secretion and urinary calcium excretion by transducing calcium concentration changes into multiple intracellular signaling cascades in the parathyroid glands and kidneys. In the parathyroid glands, the CaSR has been shown to couple to the Gα_{11} protein family, which activates phospholipase C (PLC), thereby increasing intracellular calcium ([Ca^{2+}]) and MAPK signaling responses (8, 9), which in turn leads to decreased parathyroid PTH secretion.

FHH is a genetically heterogeneous disorder with 3 recognized forms referred to as FHH types 1–3 (FHH1-3) (1). FHH1 (OMIM 145980) is caused by heterozygous loss-of-function mutations of the CaSR, which is encoded by the CASR gene on chromosome 3q21.1 (1). FHH2 (OMIM 145981) is due to heterozygous loss-of-function mutations of G-protein subunit α_{11} (Gα_{11}), which is encoded by the GNA11 gene on chromosome 19p13.3, and to date, 3 FHH2-associated mutations have been reported, comprising 2 missense mutations, Thr54Met and Leu135Gln, and an in-frame isoleucine deletion at codon 200 (Ile200del) (3, 10). FHH3 (OMIM 600740) is caused by heterozygous loss-of-function mutations of the adaptor protein-2 σ subunit (AP2σ), encoded by the AP2S1 gene on chromosome 19q13.3, which is involved in the clathrin-mediated endocytosis of cell-surface proteins such as the CaSR (4, 11).
A mouse model for FHH1 has previously been generated by targeted germline disruption of the Casr gene, and heterozygous (Casr+) mice were shown to have a phenotype resembling that of FHH1 patients with elevated serum concentrations of calcium and PTH, and low urinary calcium excretion (12). In addition, homozygous (Casr−/−) mice had features of neonatal severe hyperparathyroidism (NSHPT), which is caused by biallelic inactivating CaSR mutations (1), and exhibited growth retardation and died within the first 30 days of life (12). An in vivo model is not available for FHH2, although mice with parathyroid-specific combined ablations of both the Gnaq and Gna11 (encoding Gα11) genes have previously been reported to develop marked hypercalcemia and hyperparathyroidism (7). We therefore sought to establish a mouse model for FHH2 to define the in vivo role of Gα11 in Ca2+ homeostasis and to undertake a more detailed characterization of the phenotype of this disorder, as limited information is available from the few FHH2 patients reported, to date (3, 10). In addition, a mouse model for FHH2 would facilitate evaluation of therapeutic drugs such as CaSR allosteric activators, also known as calcimimetics (13). To establish a mouse model for FHH2, due to a germline loss-of-function GNA11 point mutation (3, 10), we screened a DNA archive of >10,000 samples from male mice that had mutations induced by treating them with N-ethyl-N-nitrosourea (ENU), a chemical mutagen. ENU is an alkylating agent that introduces point mutations via transfer of an alkyl group from ENU to a DNA base, thus leading to mispairing and bp substitution during subsequent DNA replication (14, 15). ENU mutagenesis programs utilize two complementary approaches that are phenotype-driven and genotype-driven screens. In phenotype-driven screens, offspring of mutagenized mice are assessed for abnormalities in a hypothesis-generating strategy, which may elucidate new genes, pathways, and mechanisms for disease phenotypes (14, 15). Genotype-driven screens in which mutations in the gene of interest are sought are hypothesis driven and are feasible by available parallel archives of tissue-DNA and sperm samples from mutagenized male mice (14, 15). The archived tissue-DNA samples from the mutagenized male mice are used to search for the mutations in the gene of interest, and once these mutations are found, a sperm sample from the male mouse with the mutation is used for in vitro fertilization (IVF) of normal female mice to establish progeny with the mutation (14, 15). The probability of finding 3 or more variant alleles in an archive of tissue-DNA samples from >5,000 ENU-mutagenized mice is >90% (14). We sought for ENU-induced Gna11 variants in tissue-DNA samples from >10,000 male mice treated with ENU, with the aim of establishing a mouse model for FHH2.

Results
Identification and analysis of 5 Gna11 variants in ENU-mutagenized mice. An analysis using melting curve analysis (16) of tissue-DNA samples from >10,000 ENU-mutagenized male mice of the 7 exons and 12 intron-exon boundaries of the Gna11 gene revealed the presence of 5 Gna11 variants, comprising c.379C>T, c.395T>A, c.440G>A, c.584A>G, and c.806T>C (numbering starts from ATG; Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.96540DS1; numbering in Supplemental Table 1 starts from 5′UTR.). These 5 Gna11 variants predicted the occurrence of 4 missense variants (Ile132Asn, Arg147His, Asp195Gly, and Val269Ala) and 1 nonsense variant (Gln127Stop) (Figure 1A and Supplemental Figure 1). Bioinformatic analysis predicted all the Gα11 variants to be damaging and likely disease-causing (Supplemental Table 1). FHH2 has been reported to be caused by either an in-frame deletion or missense substitutions affecting Gα11 (3, 10), and we therefore further characterized only the 4 missense Gα11 variants identified in ENU-mutagenized mice. All of these 4 missense variants affected evolutionary-conserved residues (Figure 1B, Supplemental Table 1, and Supplemental Figure 1), and 2 variants (Asp195Gly and Val269Ala) were located in the Gα11 GTPase domain, which mediates GPCR binding, guanosine triphosphate (GTP) hydrolysis, and effector coupling. The other 2 variants (Ile132Asn and Arg147His) were located in the Gα11 helical domain, which stabilizes guanine nucleotide binding (Figure 1A and Supplemental Figure 1) (17).

Three-dimensional (3-D) modeling using the reported crystal structure of the related Gαq protein (18) predicted the Asp195Gly variant to disrupt polar contacts within the Gα11 GTPase domain (Figure 1, C and D), whereas the other missense variants were not predicted to alter intramolecular interactions within the Gα11 protein (Supplemental Figure 1). We therefore selected the Asp195Gly (D195G) variant for functional characterization for the following 4 reasons. First, this variant is located within the switch regions of the Gα11 GTPase domain (Figure 1, B and C), which are critical for mediating Gα-subunit conformational changes upon GTP binding and also for coupling to downstream effector proteins such as PLC (19, 20). Second, the Asp195Gly variant is situated within a 13 amino acid region (residues 193–205), which links switches I and II (Figure 1, B and C) and is the location of a reported FHH2-causing Gα11 mutation (Ile200del) (3). Third, this 13–amino acid linker region also contains the tetrapeptide β2–β3 loop (residues 196–199), which mediates G-protein–GPCR inter-
actions (21) (Figure 1C), and our reported mutagenesis studies have shown that disruption of the Gα11β2-β3 loop impairs signaling in CaSR-expressing cells (3). Fourth, 3-D modeling of the Asp195Gly Gα11 variant predicted that substitution of the WT Asp195 residue with the variant Gly195 residue would lead to a loss of a polar contact within the Gα11β2-β3 loop, which would likely disrupt this tetrapeptide loop (Figure 1D) and thereby impair GPCR binding and Gα11 activation (3, 19, 20). These combined observations indicated that the Asp195Gly variant was highly likely to be a pathogenic mutation.

**In vitro functional characterization of the Asp195Gly Gα11 mutation.** To investigate the effects of these predicted Gα11 structural changes due to the Asp195Gly mutation on CaSR-mediated signaling, human embryonic kidney 293 (HEK293) cells stably expressing the CaSR (HEK-CaSR) were transiently transfected with pBI-CMV2-GNA11-GFP constructs expressing either the WT (Asp195) or variant (Gly195) Gα11 proteins, as reported (3). This bidirectional pBI-CMV2 vector allows for coexpression of Gα11 and GFP at equivalent levels (3). Expression of the CaSR, Gα11, and GFP was confirmed by fluorescence microscopy and/or Western blot analyses (Figure 2, A and B). The expression of Gα11 was shown to be similar in cells transiently transfected with WT or mutant proteins and to be greater than that observed in untransfected cells (Figure 2B). Moreover, the expression of mutant Gα11 in cells that endogenously express WT Gα11 (Figure 2B) corresponded to the heterozygous situation reported in FHH2 patients (3, 10). The Ca2+ responses to alterations in [Ca2+]o of cells expressing the different GNA11 vectors were assessed using a multiwell assay that utilized the Fluo-4 Ca2+-binding dye, as reported (22). The Ca2+ responses were shown to increase in a dose-dependent manner following stimulation with increasing [Ca2+]o (Figure 2C). However, responses in mutant Gly195–expressing
cells were significantly decreased compared with WT-expressing cells (Figure 2C). Thus, the mutant Gly195–expressing cells showed a rightward shift in the concentration-response curve (Figure 2C), with a significantly increased mean half-maximal response ($EC_{50}$) of 3.39 mM (95% CI, 3.26–3.53 mM) compared with 2.70 mM (95% CI, 2.53–2.88 mM) for WT-expressing (Asp195) cells ($P < 0.0001$) (Figure 2, C and D). These results demonstrated that the $G_{\alpha11}$Asp195Gly mutation is a loss-of-function mutation, similar to mutations that lead to FHH2 (3, 10). We next investigated the ability of the CaSR allosteric activator, cinacalcet, to rectify this loss of function associated with the Asp195Gly $G_{\alpha11}$ mutation. Cinacalcet was added to Gly195 mutant cells at a 10 nM concentration, as this dose has previously been reported to normalize the altered signaling responses associated with FHH2-causing $G_{\alpha11}$ mutations in vitro (23). An assessment of $Ca^{2+}$ responses showed 10 nM cinacalcet to induce a leftward shift of the concentration-response curve of cells expressing the Gly195 mutant $G_{\alpha11}$ protein (Figure 2C) and decrease their mean $EC_{50}$ value to 2.70 mM (95% CI, 2.60–2.80 mM), a value that was indistinguishable from the $EC_{50}$ of untreated WT cells (Figure 2, C and D). Thus, cinacalcet normalized the signaling responses of Gly195 mutant cells.
In vivo functional analysis in mice harboring the germline Gna11 Asp195Gly mutation. To investigate the in vivo effects of the Asp195Gly Gα11 mutation on Ca\textsuperscript{2+} homeostasis, ENU mutagenesis–derived mice harboring this mutation were established on the C3H inbred genetic background (24). DNA sequence analysis confirmed the mutant mice to harbor a germline A-to-G transition at c.584A>G at codon 195 of the Gα11 protein resulting in an Asp (D) to Gly (G) missense substitution (Figure 3, A and B). This A-to-G transition was predicted to lead to a missense substitution of Asp, encoded by GAC, to Gly, encoded by GCC, at codon 195 and resulted in the gain of a HaeIII restriction endonuclease (RE) site (GG/CC). (C) Restriction maps showing that HaeIII digest would result in 2 products of 108 bp and 225 bp for the WT, and 3 products of 108 bp, 146 bp, and 79 bp for the mutant (m). (D) RE digest of Gna11 exon 3 PCR products demonstrating that WT (Gna11+/+) mice are homozygous for the WT alleles, mutant Gna11+/195G mice are heterozygous and have WT and m alleles, and mutant Gna11195G/195G mice are homozygous for m alleles. M, male; F, female; S, size marker.

**Table 1. Proportion of offspring bred from crosses of Gna11+/195G × Gna11+/195G mice**

| Genotype | Expected number of offspring (n = 358 born) | Observed number of offspring (n = 234 weaned) |
|----------|-------------------------------------------|---------------------------------------------|
| +/+      | 89 (25%)                                  | 56 (24%)                                    |
| +/195G   | 180 (50%)                                 | 127 (54%)                                   |
| 195G/195G| 89 (25%)                                  | 51 (22%)                                    |

The Mendelian inheritance expected ratio from heterozygous crosses is 1:2:1, and \( \chi^2 \) analysis shows no significant differences in the expected vs. observed ratios of offspring genotypes at weaning (i.e., 19–21 days of age) (\( \chi^2 = 1.0, \) degrees of freedom = 2).
Table 2. Age, weight, and plasma biochemical profile of Gna11+/+ , Gna11+/195G, and Gna11195G/195G mice

| Parameter     | Male   | Gna11+/+ | Gna11195G/195G | Female | Gna11195G/195G |
|---------------|--------|----------|----------------|--------|----------------|
| Age (weeks)   | 13.9 ± 0.1 (n = 12) | 14.0 ± 0.1 (n = 13) | 13.9 ± 0.1 (n = 14) | 13.8 ± 0.1 (n = 10) | 13.8 ± 0.1 (n = 15) |
| Weight (g)    | 31.7 ± 0.7 (n = 12) | 31.4 ± 1.1 (n = 13) | 32.3 ± 0.9 (n = 14) | 27.5 ± 0.8 (n = 13) | 30.2 ± 0.9 (n = 15) |
| Sodium (mmol/l) | 149 ± 0.7 (n = 12) | 151 ± 0.5 (n = 13) | 150 ± 0.6 (n = 13) | 149 ± 0.6 (n = 10) | 148 ± 0.7 (n = 15) |
| Potassium (mmol/l) | 5.4 ± 0.1 (n = 12) | 5.2 ± 0.1 (n = 13) | 5.3 ± 0.1 (n = 13) | 5.0 ± 0.1 (n = 10) | 4.9 ± 0.1 (n = 15) |
| Urea (mmol/l)  | 10.7 ± 0.6 (n = 12) | 9.8 ± 0.3 (n = 13) | 10.1 ± 0.4 (n = 13) | 8.6 ± 0.6 (n = 10) | 8.8 ± 0.2 (n = 15) |
| Creatinine (µmol/l) | 11.6 ± 0.6 (n = 12) | 10.8 ± 0.7 (n = 13) | 12.0 ± 0.7 (n = 13) | 12.7 ± 0.4 (n = 10) | 12.8 ± 0.4 (n = 15) |
| Calcium (mmol/l) | 2.36 ± 0.02 (n = 12) | 2.40 ± 0.02 (n = 12) | 2.48 ± 0.02 (n = 13) | 2.40±0.03 (n = 10) | 2.46 ± 0.01 (n = 15) |
| Adj-calcium (mmol/l)<sup>a</sup> | 2.36 ± 0.02 (n = 12) | 2.41 ± 0.02 (n = 12) | 2.48 ± 0.02 (n = 13) | 2.39 ± 0.02 (n = 10) | 2.45 ± 0.01 (n = 15) |
| Albumin (g/l)  | 25.2 ± 0.3 (n = 12) | 24.8 ± 0.3 (n = 13) | 25.0 ± 0.2 (n = 13) | 26.2 ± 0.4 (n = 10) | 26.5 ± 0.4 (n = 15) |
| Magnesium (mmol/l) | 0.80 ± 0.02 (n = 12) | 0.76 ± 0.02 (n = 13) | 0.76 ± 0.02 (n = 13) | 0.81 ± 0.02 (n = 10) | 0.83 ± 0.02 (n = 15) |
| Phosphate (mmol/l) | 1.67 ± 0.11 (n = 12) | 1.65 ± 0.08 (n = 13) | 1.51 ± 0.08 (n = 13) | 2.04 ± 0.12 (n = 10) | 1.73 ± 0.05 (n = 15) |
| ALP (U/l)      | 93.2 ± 3.3 (n = 12) | 90.8 ± 4.9 (n = 13) | 98.5 ± 3.2 (n = 13) | 120 ± 4.5 (n = 10) | 132 ± 3.5 (n = 15) |
| PTH (ng/l)     | 417 ± 37 (n = 8)    | 562 ± 54 (n = 12)   | 813 ± 63 (n = 13)<sup>g</sup> | 290 ± 34 (n = 10)   | 405 ± 43 (n = 12)   |
| 1,25D (pmol/l) | 74.5 ± 11 (n = 12)  | 64.7 ± 10 (n = 10)  | 90.7 ± 19 (n = 12)  | 72.8 ± 9 (n = 9)    | 76.8 ± 6 (n = 14)   |
| FGF-23 (ng/l)  | 149 ± 7 (n = 12)    | 170 ± 5 (n = 11)    | 173 ± 8 (n = 12)    | 150 ± 4 (n = 10)    | 146 ± 7 (n = 14)    |

<sup>a</sup>Plasma calcium concentrations were adjusted according to the mean plasma albumin concentration of respective male and female WT mice. Adj-calcium, albumin-adjusted calcium; ALP, alkaline phosphatase activity; PTH, parathyroid hormone; 1,25D, 1,25-dihydroxyvitamin D; FGF-23, fibroblast growth factor-23. All values are expressed as mean ± SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used to compare mutant mice with WT mice, and a Mann-Whitney U test was used to compare respective male and female mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared with respective Gna11+/+ mice. †P < 0.001 compared with respective male mice.

plasma PTH concentrations when compared with Gna11+/+ mice, whereas Gna11195G/195G mice had plasma phosphate and PTH concentrations that were similar to those of Gna11+/+ mice (Figure 4, B and C). Furthermore, the fractional excretion of calcium was not altered in Gna11195G/195G or Gna11195G/195G mice compared with Gna11+/+ mice (Figure 4D and Table 3). However, there were sex differences in these calcitropic phenotypes, as follows. Female Gna11195G/195G mice were significantly more hypercalcemic than male Gna11195G/195G mice and female Gna11+/+ mice (Table 2 and Supplemental Figure 2). In addition, female Gna11195G/195G mice, but not the Gna11 mutant males, had significant hypophosphatemia, with a significant reduction in the tubular maximum reabsorption of phosphate (Table 3) and a raised alkaline phosphatase activity compared with female Gna11+/+ mice (Table 2 and Supplemental Figure 2). Significant differences were not observed in plasma electrolytes, urea and creatinine concentrations, or 1,25-dihydroxyvitamin D or fibroblast growth factor-23 (FGF-23) concentrations in male or female Gna11195G and Gna11195G/195G mice, when compared with respective Gna11+/+ mice (Table 2). The fractional excretions of sodium and potassium were also not different between male and female mutant mice and respective Gna11+/+ mice (Table 3). Finally, whole body dual-energy X-ray absorptiometry (DXA) did not reveal significant differences in the bone mineral content or bone mineral density (BMD) between male and female mutant mice and respective Gna11+/+ mice (Table 4).

To determine whether the hypercalcemia of Gna11195G and Gna11195G/195G mice may be improved by in vivo calcimimetic treatment, we administered cinacalcet to WT and mutant mice. A pilot dose-ranging study in WT mice showed that a single oral gavage 30 mg/kg dose of cinacalcet significantly lowered plasma PTH concentrations, when compared with vehicle-treated mice (Supplemental Figure 3). This dose (30mg/kg) of cinacalcet was therefore administered by oral gavage to Gna11+/+ , Gna11195G/195G, and Gna11195G/195G mice, and plasma samples were then taken at 0, 1, 2, 4, 6, and 24 hours after dose for the measurement of PTH, calcium, phosphate, urea, creatinine, and albumin concentrations. Administration of cinacalcet significantly decreased plasma PTH concentrations in Gna11+/+ , Gna11195G/195G, and Gna11195G/195G mice by ≥ 60% at 1 hour after dose, with values returning to baseline by 4–6 hours after dose (Figure 5, A–C), and it significantly reduced plasma albumin-adjusted calcium concentrations in Gna11+/+ , Gna11195G/195G, and Gna11195G/195G mice between 2–6 hours after dose, with values returning to
baseline by 24 hours after dose (Figure 5, D–F). Cinacalcet treatment also resulted in a transient rise in plasma phosphate concentrations in Gna11+/+, Gna11+/195G, and Gna11195G/195G mice (Figure 5, G–I) but was not associated with any increases in plasma concentrations of urea or creatinine (Supplemental Figure 4). Thus, these studies demonstrated that cinacalcet is effective in vivo and can reduce raised plasma calcium and PTH concentrations observed in Gna11 mutant mice with a loss-of-function Gna11 mutation, which is representative of FHH2.

**Discussion**

We have established a mouse model for FHH2, and this will enable the calcitropic roles of Gna11 to be further evaluated and also facilitate further pathophysiological studies that are difficult to pursue in the few reported patients with this condition. Our results revealed that heterozygous-affected (Gna11+/195G) mice had a similar plasma biochemical phenotype to that reported for FHH2 patients, who also harbor heterozygous loss-of-function Gna11 mutations (Table 5) (3, 10). Thus, Gna11+/195G mice had mild hypercalcemia in association with normal plasma PTH concentrations; they also had no alterations in the plasma concentrations of phosphate and creatinine, or in alkaline phosphatase activity, which is consistent with

---

**Table 3. Urine biochemical profile of Gna11+/+, Gna11+/195G, and Gna11195G/195G mice**

| Parameter | Male | Female |
|-----------|------|--------|
|          | Gna11+/+ | Gna11+/195G | Gna11195G/195G | Gna11+/+ | Gna11+/195G | Gna11195G/195G |
| 24hr Ca  | 4.9 ± 0.4 (n = 9) | 5.9 ± 0.5 (n = 13) | 6.4 ± 0.7 (n = 13) | 11.7 ± 3.1 (n = 10) | 16.3 ± 2.4 (n = 15) | 17.0 ± 1.7 (n = 12) |
| Ca/Cr    | 0.30 ± 0.12 (n = 9) | 0.31 ± 0.02 (n = 12) | 0.32 ± 0.02 (n = 12) | 0.57 ± 0.06 (n = 10) | 0.75 ± 0.10 (n = 15) | 0.88 ± 0.13 (n = 12) |
| FENA     | 1.9 ± 0.3 (n = 11) | 1.5 ± 0.3 (n = 13) | 1.4 ± 0.2 (n = 12) | 2.9 ± 0.3 (n = 10)* | 3.1 ± 0.3 (n = 13)* | 3.0 ± 0.2 (n = 9)* |
| FENA     | 5.3 ± 0.4 (n = 12) | 4.7 ± 0.4 (n = 13) | 5.2 ± 0.5 (n = 13) | 6.1 ± 0.2 (n = 10) | 6.1 ± 0.3 (n = 15) | 6.0 ± 0.3 (n = 13) |
| FENa     | 0.20 ± 0.004 (n = 11) | 0.18 ± 0.002 (n = 13) | 0.20 ± 0.001 (n = 13) | 0.21 ± 0.01 (n = 10) | 0.23 ± 0.01 (n = 15) | 0.21 ± 0.01 (n = 13) |
| TmP/GFR  | 1.6 ± 0.1 (n = 12) | 1.6 ± 0.1 (n = 12) | 1.5 ± 0.1 (n = 12) | 2.0 ± 0.1 (n = 10) | 1.7 ± 0.1 (n = 15)* | 1.6 ± 0.1 (n = 13)* |

Parameters were measured using urine samples obtained over a 24-hour period. Urinary calcium excretion values are shown as μmol/24 hours. Calcium/creatinine ratios (Ca/Cr) are shown as mmol/mmol. Fractional excretion (FE) of Ca and Na are multiplied by 1,000. TmP/GFR, ratio of tubular maximum reabsorption of phosphate (TmP) to GFR. All values are expressed as mean ± SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used for all analyses. *P < 0.05 compared with respective Gna11+/+ mice. †P < 0.05, ‡P < 0.001 compared with respective male mice.
The reported phenotype of FHH2 patients (Table 5) (3, 10). Gna11<sup>+/195G</sup> mice additionally had normal plasma magnesium concentrations, which is consistent with one reported FHH2 proband (3) but which contrasts with the hypermagnesemia reported in a multigenerational FHH2 kindred (3). A key finding of this study is that Gna11<sup>+/195G</sup> and Gna11<sup>195G/195G</sup> mice had no alterations in urinary calcium excretion, and this would be consistent with studies of FHH2 patients, which have reported that not all FHH2 patients have a low fractional excretion of calcium (Table 5) (3, 10). The absence of a urinary calcium phenotype in Gna11<sup>+/195G</sup> and Gna11<sup>195G/195G</sup> mice is also consistent with the reported findings in mice and humans harboring germline gain-of-function G<sub>α</sub>q mutations that is associated with hypocalcemia and reduced plasma PTH concentrations but with mild or no alterations in urinary calcium excretion (25–27). These studies highlight a potential difference in the calcitropic phenotype of disorders caused by germline G<sub>α</sub>q mutations and that of disorders caused by germline CaSR mutations, and they suggest that the G<sub>α</sub>q protein may not play a major role in the renal handling of calcium. Thus, it remains to be established whether hypocalciuria represents a major component of the FHH2 disorder in humans. Furthermore, DXA analysis did not reveal any alterations in the BMD values of Gna11<sup>195G/195G</sup> mice, which also suggests that the G<sub>α</sub>q protein may not influence bone mass.

Our studies of homozygous-affected (Gna11<sup>195G/195G</sup>) mice have highlighted the importance of G<sub>α</sub>q for parathyroid gland function and PTH secretion, as Gna11<sup>195G/195G</sup> mice had more pronounced hypercalcemia and hypophosphatemia, and significantly raised plasma PTH concentrations, consistent with primary hyperparathyroidism (28). Moreover, female Gna11<sup>195G/195G</sup> mice also had significant elevations of plasma alkaline phosphatase activity, which is consistent with an elevated bone turnover associated with this likely primary hyperparathyroidism. However, the hypercalcemic phenotype of Gna11<sup>195G/195G</sup> mice was, in general, milder than that observed in humans or mice harboring biallelic loss-of-function CaSR mutations, which typically lead to the life-threatening disorder of NSHPT (12, 24). A possible explanation for the milder hypercalcemic phenotype observed in the Gna11<sup>195G/195G</sup> mice is that the loss of G<sub>α</sub>q function caused by the Asp195Gly mutation in vivo was partially compensated by the WT G<sub>α</sub>q protein, which in the parathyroid glands continues to mediate signal transduction by the CaSR. Indeed, the importance of the G<sub>α</sub>q and G<sub>α</sub>q proteins for parathyroid gland function has been demonstrated by studies of mice with a parathyroid-specific ablation of both G<sub>α</sub>q and G<sub>α</sub>q, which have been reported to develop features of NSHPT such as severe hypercalcemia, skeletal demineralization, growth retardation, and early postnatal death (7). The hypercalcemia observed in Gna11<sup>195G/195G</sup> mice was more severe in females compared with males, and such sex differences have not previously been reported in studies of FHH patients. However, sex differences have been noted in primary hyperparathyroidism patients, with females being more commonly affected than males (29). Moreover, estrogen may play a role in the pathogenesis and severity of primary hyperparathyroidism, as highlighted by a study that showed the potential involvement of estrogen signaling in parathyroid function and disease (30); such effects may have contributed to the more severe hypercalcemia of female Gna11<sup>195G/195G</sup> mice.

There is currently no effective treatment for FHH2, and we therefore evaluated the therapeutic potential of cinacalcet, which is a licensed CaSR-positive allosteric modulator (13), for this condition.

### Table 4. Whole body DXA analysis of Gna11<sup>+/+</sup>, Gna11<sup>+/195G</sup>, and Gna11<sup>195G/195G</sup> mice

| Parameter          | Male                                   | Female                                  |
|--------------------|----------------------------------------|-----------------------------------------|
|                    | Gna11<sup>+/+</sup> | Gna11<sup>+/195G</sup> | Gna11<sup>195G/195G</sup> | Gna11<sup>+/+</sup> | Gna11<sup>+/195G</sup> | Gna11<sup>195G/195G</sup> |
| BMC (g)            | 0.60 ± 0.01 (n = 12) | 0.62 ± 0.01 (n = 13) | 0.63 ± 0.01 (n = 14) | 0.57 ± 0.01 (n = 9) | 0.59 ± 0.01 (n = 14) | 0.57 ± 0.01 (n = 12) |
| BMC (corr)         | 0.02 ± 0.0004 (n = 12) | 0.02 ± 0.0001 (n = 13) | 0.02 ± 0.0001 (n = 14) | 0.02 ± 0.0001 (n = 9) | 0.02 ± 0.0001 (n = 15) | 0.019 ± 0.0001 (n = 12) |
| BMD (g/cm<sup>2</sup>) | 0.065 ± 0.001 (n = 12) | 0.065 ± 0.001 (n = 13) | 0.065 ± 0.002 (n = 14) | 0.067 ± 0.001 (n = 9) | 0.066 ± 0.001 (n = 15) | 0.067 ± 0.003 (n = 12) |
| Fat mass (%)       | 23.6 ± 0.8 (n = 12) | 21.3 ± 1.1 (n = 13) | 22.0 ± 1.4 (n = 14) | 23.8 ± 1.9 (n = 9) | 27.4 ± 1.5 (n = 15) | 29.0 ± 0.7<sup>76</sup> (n = 12) |

DXA, dual-energy X-ray absorptiometry; BMC, bone mineral content; BMC (corr), BMC corrected for body weight; BMD, bone mineral density. All values are expressed as mean ± SEM. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used for all analyses.

*P = 0.06 compared with respective Gna11<sup>+/+</sup> mice.
In vitro studies have previously reported that nanomolar concentrations of cinacalcet can successfully rectify the altered signaling responses of HEK-CaSR cells expressing FHH2-associated Gα11 mutant proteins (23). Consistent with these findings, our study showed a 10 nM concentration of cinacalcet to normalize the Ca\textsuperscript{2+} responses of HEK-CaSR cells expressing the mutant Gly195 Gα11 protein. Moreover, oral administration of a single 30 mg/kg cinacalcet dose led to a transient suppression of PTH secretion in Gna11\textsuperscript{+/+}, Gna11\textsuperscript{+/195G}, and Gna11\textsuperscript{195G/195G} mice, and this was associated with a sustained reduction in plasma calcium concentrations, which lasted for ≥ 6 hours. This dose of cinacalcet was well tolerated in the mice and did not lead to hypocalcemia, with mean plasma calcium concentrations remaining at > 2.0 mmol/l. However, transient hyperphosphatemia was noted in cinacalcet-treated mice, which was likely to be a consequence of suppressed PTH secretion (31). These results suggest that calcimetics such as cinacalcet will likely be of benefit for FHH2 patients, who also harbor loss-of-function Gα11 mutations (23).

In summary, we have established a mouse model for FHH2 and have shown the in vivo efficacy of cinacalcet in reducing plasma calcium and PTH concentrations, thereby illustrating the potential utility of this CaSR allosteric modulator for the treatment of hypercalcemia in patients with FHH2.

Figure 5. In vivo effect of cinacalcet on plasma PTH, calcium, and phosphate concentrations of Gna11\textsuperscript{+/+}, Gna11\textsuperscript{+/195G}, and Gna11\textsuperscript{195G/195G} mice. (A–C) Plasma parathyroid hormone (PTH), (D–F) plasma albumin–adjusted calcium, and (G–I) plasma phosphate concentrations are shown at 0, 1, 2, 4, 6, and 24 hours following oral gavage administration of a single 30 mg/kg cinacalcet dose. Mean values for the respective groups are indicated by solid bars. n = 4–5 mice per study time point. Squares, males; circles, females. A Kruskal-Wallis test followed by Dunn’s test for nonparametric pairwise multiple comparisons were used for analysis of A–I. *P < 0.05, **P < 0.01 compared with respective untreated mice. Untreated Gna11\textsuperscript{195G/195G} mice were significantly (P < 0.05) hypercalcemic compared with untreated Gna11\textsuperscript{+/+} mice.
Table 5. Comparison of the phenotypes of FHH2 patients with mice harboring a loss-of-function Gna11 mutation

| Parameter | FHH2 patients | FHH2 mouse model |
|-----------|---------------|------------------|
| **Gna11 mutation** | **Proband 1** | **Proband 2** | **Proband 3** | **Gna11<sup>+/+</sup>** | **Gna11<sup>−/−</sup>** |
| CA<sub>β</sub> | Leu135Gln (Het) | Ile200del (Het) | Thr54Met (Het) | Asp195Gly (Het) | Asp195Gly (Hom) |
| Serum/plasma biochemistry | | | | | |
| Calcium | H | H | H | H | H |
| Magnesium | N | N | N | N | N |
| Phosphate | N | N | N | N | N |
| Creatinine | N | N | N | N | N |
| ALP | N | N | N | N | N |
| PTH | N | N | N | N | N |
| TSH<sup>a</sup> | N | nr | nr | nr | nr |
| Urine biochemistry | | | | | |
| FECa<sup>b</sup> | L<sup>c</sup> | N | N | N | N |
| Infertility<sup>a</sup> | nr | No | nr | No | nr |
| Reference | Nesbit et al. 2013 (3) | Nesbit et al. 2013 (3) | Gorvin et al. 2016 (10) | - | - |

<sup>a</sup>Alkaline phosphatase (ALP) is increased in homozygous females; <sup>b</sup>Thyrotropin (TSH) reported as 4.05 mU/l (normal 0.35–5.5) (3). Thyrotropin-releasing hormone receptor (TRHR) and gonadotropin-releasing hormone receptor (GnRHR), which are both GPCRs signal via G<sub>α</sub><sub>q</sub> proteins (40). However, FHH2 patients with G<sub>α</sub><sub>q</sub> loss-of-function mutations have not been reported to have high-hypothyroidism, high-circulating TSH concentrations (3), or infertility (3, 41), indicating that there are unlikely to have thyroid hormone or gonadotropin hormone deficiencies. The findings of normal body weights in mutant Gna11<sup>−/−</sup> and Gna11<sup>−/−/−</sup> mice (Table 2) and fertility in mutant Gna11<sup>−/−</sup> mice (Table 1) suggest that these Gna11 mutant mice, similar to the FHH2 patients, are also unlikely to have deficiencies of thyroid hormone or gonadotropin hormone. <sup>c</sup>Fractional excretion of calcium (FECa) is < 0.01, consistent with the phenotype of FHH. Het, heterozygous; Hom, homozygous; N, normal; PTH, parathyroid hormone; H, high; L, low; nr, not reported.

**Methods**

**Animals.** ENU-treated G0 C57BL/6J male mice (The Jackson Laboratory) were mated to C3H/HeH (C3H) mice (MRC Harwell) to produce G1 progeny, and tissue-DNA samples from > 10,000 G1 ENU mutagenized male mice — together with their sperm — was archived, as reported (14). These tissue-DNA samples were used to identify Gna11 variants by melt curve analysis of PCR products utilizing a Lightscanner and gene-specific primers (BioFire Diagnostics Inc.), and sperm from mice with Gna11 variants was used for IVF to generate G2 progeny on a C3H background strain, as reported (16, 24). Heterozygous-affected (Gna11<sup>+/−</sup>) mutant male and female mice were intercrossed to generate homozygous (Gna11<sup>−/−</sup>) mice, which were studied along with their Gna11<sup>−/−</sup> littermates. All study mice were housed in a controlled environment at the MRC Harwell Institute in accordance with UK Home Office and MRC Welfare guidance. Mice were fed on a standard diet (Rat and Mouse number 3, Special Diet Services) that contained 1.15% calcium, 0.58% phosphate, and 4089 IU/kg of vitamin D, and they were provided with water ad libitum (25, 32).

**Compounds.** Cinacalcet (AMG-073 HCL) was obtained from Cambridge Bioscience (catalog CAY16042) and dissolved in a 20% aqueous solution of 2-hydroxypropyl-β-cyclodextrin (MilliporeSigma), catalog H107) prior to use in in vitro and in vivo studies.

**DNA sequence analysis.** Genomic DNA was isolated from auricular biopsies using DNA extraction buffer (10 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 10% SDS; MilliporeSigma) and Proteinase K solution (Thermo Fisher Scientific) (25). Genomic DNA was used with Gna11 gene–specific primers (MilliporeSigma) to perform PCR amplification, followed by dideoxynucleotide sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit and an automated detection system (ABI 3730 Automated capillary sequencer, Thermo Fisher Scientific), as reported (25). MutationTaster (http://www.mutationtaster.org/) and Polyphen-2 software was used to predict variant pathogenicity (33, 34). The Gna11 germline mutation was confirmed by HaeIII restriction endonuclease analysis (New England Biolabs), as previously described (3, 4).

**Protein sequence alignment and 3-D modeling.** Protein sequences of G<sub>α</sub><sub>q</sub> orthologs and paralogs were aligned with Clustal Omega (35). The PyMOL Molecular Graphics System (Version 1.2r3pre, Schrödinger LLC) was used for structural modeling based on the complexed crystal structure of G<sub>α</sub><sub>q</sub> which has 90%
identity with Gα11 at the amino acid level (Protein Data Bank, accession no. 4GNK; https://www.rcsb.org/pdb/home/home.do) (18). The effect of the Gα11 mutations upon Gα11 structure was modeled using the PyMod plug-in and Modeller (36).

**Cell culture and transfection.** Functional studies were undertaken using a human GNA11 construct (3), as the human and mouse Gα11 proteins share an overall amino acid identity of 98% (25) and are 100% identical in the region surrounding the mutated site. The Gly195 mutation was introduced by site-directed mutagenesis (QuickChange Lightning, Agilent Technologies) into a pBI-CMV2-GNA11-GFP expression construct, as reported (3), and WT and mutant pBI-CMV2-GNA11-GFP constructs were transiently transfected into HEK293 cells stably expressing the full-length human CASR cDNA (HEK-CaSR), as described (3). HEK-CaSR cells were maintained in DMEM-Glutamax media (Thermo Fisher Scientific) with 10% FBS (Gibco) and 400 μg/ml geneticin (Thermo Fisher Scientific) at 37°C, 5% CO2 (3). Successful transfection was confirmed by visualizing GFP fluorescence using an Eclipse E400 fluorescence microscope with an epifluorescence filter, and images were captured using a DXM1200C digital camera and NIS Elements software (Nikon) (3, 11). The expression of Gα11, CaSR, GFP, calnexin, and GAPDH proteins was confirmed by Western blot analyses using anti-Gα11 (D-6, sc-390382, Santa Cruz Biotechnologies Inc.), anti-CaSR (5C10, ADD; ab19347; Abcam), anti-GFP (B-2, sc-9996, Santa Cruz Biotechnologies Inc.), anti-calnexin (AB2301, Millipore), and anti-GAPDH (AM4300, Ambion) antibodies, respectively. The Western blots were visualized using an Immuno-Star Western C kit (Bio-Rad) on a Bio-Rad Chemidoc XRS+ system (3, 10).

**Measurement of Ca2+ responses.** The Ca2+ responses of HEK-CaSR cells expressing WT or mutant Gα11 proteins were measured by Fluo-4 calcium assays adapted from methods previously published (22). HEK-CaSR cells were plated in poly-L-lysine–treated black-walled 96-well plates (Corning) and were transiently transfected with 1,000 μg/ml pBI-CMV2-GNA11-GFP. On the following day, cells were incubated in serum-free media for 2 hours and then loaded with the Fluo-4 Ca2+-binding dye, prepared according to manufacturer’s instructions (Invitrogen). Cells were loaded for 40 minutes at 37°C. Then, either a 20% aqueous solution of 2-hydroxypropyl-β-cyclodextrin (vehicle) or 10 nM cinacalcet was added, and cells were incubated for a further 20 minutes at 37°C (19). Baseline measurements were made, and increasing doses of CaCl2 were injected into each well, using the PHERAstar microplate reader (BMG Labtech) automated system. Changes in Ca2+ were recorded on a PHERAstar instrument (BMG Labtech) at 37°C with an excitation filter of 485 nm and an emission filter of 520 nm. The peak mean fluorescence ratio of the transient response after each individual stimulus was measured using MARS data analysis software (BMG Labtech) and expressed as a normalized response. Nonlinear regression of concentration-response curves was performed with GraphPad Prism using the normalized response at each [Ca2+]o for each separate experiment for the determination of the EC50 values.

**Metabolic cage studies and biochemical analysis.** Thirteen- to 15-week-old mice were individually housed in metabolic cages (Techniplast) for 24 hours with free access to food and water. Mice were allowed to acclimatize to their environment over a 72-hour period, as described (37), prior to collection of 24-hour urine samples. Twenty-four–hour urine samples were collected in tubes containing sodium azide, and blood samples were collected from the lateral tail vein under topical local anesthesia (38) or from the retro-orbital vein into lithium heparin Microvette tubes (Sarstedt) following terminal isoflurane anesthesia, as described (25, 32). Plasma and urine were analyzed for sodium, potassium, total calcium, phosphate, magnesium, urea, creatinine, and alkaline phosphatase activity on a Beckman Coulter AU680 analyzer (25, 32). Plasma calcium was adjusted for variations in albumin concentrations using the formula: plasma calcium (mmol/l) – (plasma albumin – mean albumin (g/l) of respective male and female WT mice) × 0.02, as reported (39). Hormones were measured as follows: PTH using a 2-site ELISA specific for mouse intact PTH (Immutopics); 1,25-dihydroxyvitamin D by a 2-step process involving purification by immunoextraction and quantification by enzyme immunoassay (ImmunoDiagnostic Systems); and FGF-23 using a 2-site ELISA kit (Kainos Laboratories), as described (25, 39). The fractional excretion of sodium, potassium, and calcium were calculated using the formula Ux/Px × Pcrea/Ucrea, where Ux is the urinary concentration of the filtered substance (substance x) in mmol/l, Px is the plasma concentration of substance x in mmol/l, Ucrea is the urinary concentration of creatinine in mmol/l, and Pcrea is the plasma concentration of creatinine in mmol/l. The ratio of tubular maximum reabsorption of phosphate to GFR (TmP/GFR) was calculated using the following formula: Pn × (1 – [Uion/Pn × Pcrea/Ucrea]), where Pn is the plasma concentration of phosphate and Uion is the urine concentration of phosphate (25, 32).
Skeletal imaging. Bone mineral content and density were assessed by whole body DXA scanning, which was performed on mice anesthetized by inhaled isoflurane and using a Lunar Piximus densitometer (GE Medical Systems), as reported (25). DXA images were analyzed using Piximus software, as reported (25).

Statistics. All in vitro studies involved 8 biological replicates. Statistical comparisons of the Ca\(^{2+}\) \(EC_{50}\) responses were undertaken using the \(F\)-test, as reported (3). For the in vivo studies, a Kruskal-Wallis test was undertaken for multiple comparisons, and any significant differences identified were further assessed using the Dunn's test for nonparametric pairwise multiple comparisons (25). All analyses were performed using GraphPad Prism (GraphPad), and a value of \(P < 0.05\) was considered significant for all analyses.

Study approval. Animal studies were approved by the MRC Harwell Institute Ethical Review Committee and were licensed under the Animal (Scientific Procedures) Act 1986, issued by the UK Government Home Office Department (PPL30/2433 and PPL30/3271).

Author Contributions
SAH, FMH, CMG, MAN, SDMB, RDC, and RVT designed research studies; SAH, CMG, AP, MS, TAH, and SW conducted experiments; SAH, FMH, CMG, and SEP acquired and analyzed data; and SAH, FMH, CMG, and RVT wrote the manuscript.

Acknowledgments
This work was supported by the United Kingdom MRC program grants G9825289 and G1000467 (to MAN, FMH, CMG and RVT). SAH was a Wellcome Trust Clinical Training Fellow; and RVT is a Welcome Trust Investigator and NIHR Senior Investigator. We thank R. Head for technical assistance.

Address correspondence to: Rajesh V. Thakker, Academic Endocrine Unit, Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), Churchill Hospital, Oxford OX3 7LJ, United Kingdom. Phone: 01865.857501; Email: rajesh.thakker@ndm.ox.ac.uk.

1. Hannan FM, Babinsky VN, Thakker RV. Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol. 2016;57(3):R127–R142.
2. Hannan FM, et al. Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet. 2012;21(12):2768–2778.
3. Nesbit MA, et al. Mutations affecting G-protein subunit α11 in hypercalcaemia and hypocalcaemia. N Engl J Med. 2013;368(26):2476–2486.
4. Nesbit MA, et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcaemia type 3. Nat Genet. 2013;45(1):93–97.
5. Hofer AM, Brown EM. Extracellular calcium sensing and signaling. Nat Rev Mol Cell Biol. 2003;4(7):530–538.
6. Conigrave AD, Ward DT. Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways. Best Pract Res Clin Endocrinol Metab. 2013;27(3):315–331.
7. Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, Spiegel AM. Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca\(^{2+}\) -sensing receptor. Mol Endocrinol. 2007;21(1):274–280.
8. Darè E, Kifor O, Brown EM, Weber G. Characterization of the phosphatidylinositol-specific phospholipase C isoforms present in the bovine parathyroid and in human kidney HEK293 cells stably transfected with the human parathyroid Ca\(^{2+}\) -sensing receptor. J Mol Endocrinol. 1998;21(1):7–17.
9. Corbetta S, Lania A, Filopanti M, Vicentini L, Ballaré E, Spada A. Mitogen-activated protein kinase cascade in human normal and tumoral parathyroid cells. J Clin Endocrinol Metab. 2002;87(5):2201–2205.
10. Gorvin CM, et al. A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalce
11. Loss-of-Function Mice.
12. Piret SE, Thakker RV. Mouse models for inherited endocrine and metabolic disorders. Annu Rev Genomics Hum Genet
13. Reagan-Beckman J, et al. G-protein-coupled receptors: origins, diversity, and function. Annu Rev Genomics Hum Genet
14. Piret SE, Thakker RV. Mouse models for inherited endocrine and metabolic disorders. Annu Rev Genomics Hum Genet
15. Piret SE, Thakker RV. Mouse models for inherited endocrine and metabolic disorders. Annu Rev Genomics Hum Genet
16. Gorvin CM, et al. N-ethyl-N-nitrosourea–Induced Adaptor Protein 2 Sigma Subunit 1 (Ap2s1) Mutations Establish Ap2s1
17. Oldham WM, Hamn HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol.
18. Lyon AM, Dutta S, Boguth CA, Skiniotis G, Tesmer JJ. Full-length Gq(α)-phospholipase C-β3 structure reveals interfaces of the C-terminal coiled-coil domain. Nat Struct Mol Biol. 2013;20(3):355–362.
19. Tesmer VM, Kawano T, Shankaranarayanan A, Kozasa T, Tesmer JJ. Snapshot of activated G proteins at the membrane: the Gαq-GRK2-Gbetagamma complex. *Science*. 2005;310(5754):1686–1690.
20. Waldo GL, et al. Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex. *Science*. 2010;330(6006):974–980.
21. Flock T, Hauser AS, Lund N, Gloriam DE, Balaji S, Babu MM. Selectivity determinants of GPCR-G-protein binding. *Nature*. 2017;545(7654):317–322.
22. Leach K, et al. Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. *Cell Res*. 2016;26(5):574–592.
23. Babinsky VN, et al. Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalccemic and Hypocalcemic Disorders. *J Biol Chem*. 2016;291(20):10876–10885.
24. Loh NY, et al. Autosomal dominant hypercalciuria in a mouse model due to a mutation of the epithelial calcium channel, TRPV5. *PLoS ONE*. 2013;8(1):e55412.
25. Gorvin CM, et al. Gq11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy. *JCI Insight*. 2017;2(3):e91103.
26. Leach K, et al. Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. *J Clin Endocrinol Metab*. 2014;99(9):E1774–E1783.
27. Roszko KL, et al. Knockin mouse with mutant Gq11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. *JCI Insight*. 2017;2(3):e91079.
28. Fraser WD. Hyperparathyroidism. *Lancet*. 2009;374(9684):145–158.
29. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. *J Bone Miner Res*. 2002;17 Suppl 2:N18–N23.
30. Haugland F, et al. Evidence of a functional estrogen receptor in parathyroid adenomas. *J Clin Endocrinol Metab*. 2012;97(12):4631–4639.
31. Howles SA, et al. Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations. *N Engl J Med*. 2016;374(14):1396–1398.
32. Haman FM, et al. The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). *Endocrinology*. 2015;156(9):3114–3121.
33. Adzhubei IA, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248–249.
34. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods*. 2014;11(4):361–362.
35. Sievers F, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol*. 2011;7:539.
36. Bramucci E, Piaardi A, Bossa F, Pascarella S. PyMod: sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL. *BMC Bioinformatics*. 2012;13 Suppl 4:S2.
37. Stechman MJ, et al. Establishing normal plasma and 24-hour urinary biochemistry ranges in C3H, BALB/c and C57BL/6J mice following acclimatization in metabolic cages. *Lab Anim*. 2010;44(3):218–225.
38. Bentley L, et al. An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess. *Endocrinology*. 2014;155(3):908–922.
39.Esapa CT, et al. N-ethyl-N-Nitrosourea (ENU) induced mutations within the klotho gene lead to ectopic calcification and reduced lifespan in mouse models. *PLoS ONE*. 2015;10(4):e0122650.
40. Hsieh KP, Martin TF. Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins Gq and G11. *Mol Endocrinol*. 1992;6(10):1673–1681.
41. Heath H, Leppert MF, Lifton RP, Penniston JT. Genetic linkage analysis in familial benign hypercalcemia using a candidate gene strategy. I. Studies in four families. *J Clin Endocrinol Metab*. 1992;75(3):846–851.